Zhejiang Medicine Co., Ltd. (SHA:600216)

China · Delayed Price · Currency is CNY

13.33

-0.08 (-0.60%)

Aug 14, 2026, 3:00 PM CST

-15.79% (1Y)

Market Cap	12.64B -17.0%
Revenue (ttm)	8.82B -6.0%
Net Income	751.31M -48.5%
EPS	0.78 -49.3%
Shares Out	947.91M
PE Ratio	17.07
Forward PE	13.33
Dividend	0.28 (2.10%)
Ex-Dividend Date	Jul 9, 2026

Volume	44,074,926
Open	13.24
Previous Close	13.41
Day's Range	13.15 - 13.54
52-Week Range	10.94 - 18.58
Beta	0.32
Analysts	Buy
Price Target	17.00 (+27.53%)
Earnings Date	Aug 26, 2026

About Zhejiang Medicine

Zhejiang Medicine Co., Ltd. manufactures and sells life nutrition and pharmaceuticals products in China and internationally. The company offers synthetic vitamin E, vitamin A, natural vitamin E, β-carotene, canthaxanthin, vancomycin hydrochloride, teicoplanin, and daptomycin. It also provides fat-soluble vitamins, quinolone antibiotics, anti-drug-resistant antibiotics, and other products, as well as animal nutrition products. In addition, the company offers injectable levofloxacin lactate, vancomycin hydrochloride injection, and injectable teic... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1997

Employees 5,417

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 600216

Full Company Profile

Financial Performance

In 2025, Zhejiang Medicine's revenue was 8.88 billion, a decrease of -5.28% compared to the previous year's 9.38 billion. Earnings were 873.38 million, a decrease of -24.74%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 600216 stock is "Buy." The 12-month stock price target is ¥17.00, which is an increase of 27.53% from the latest price.

Price Target

¥17.00

(27.53% upside)

Analyst Consensus: Buy

Stock Forecasts